Passage Bio Inc
NASDAQ:PASG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Passage Bio Inc
NASDAQ:PASG
|
US |
|
Kuehne und Nagel International AG
SIX:KNIN
|
CH |
|
Infineon Technologies AG
XETRA:IFX
|
DE |
|
New York Community Bancorp Inc
NYSE:NYCB
|
US |
|
S
|
Sekisui House Ltd
XMUN:SPH1
|
JP |
|
Credit Agricole SA
MIL:1ACA
|
FR |
|
M
|
MGIC Investment Corp
XBER:MGC
|
US |
|
Catena AB
F:T9R
|
SE |
|
Delek Logistics Partners LP
NYSE:DKL
|
US |
|
G
|
Green Plains Inc
XBER:G3V
|
US |
|
Realty Income Corp
NYSE:O
|
US |
Passage Bio Inc
Passage Bio is a biotechnology company that develops gene therapies for rare genetic diseases, especially disorders that affect the brain and nervous system. Its main work is to design treatments that replace or repair faulty genes, with a focus on diseases that have few or no good treatment options. The company does not sell a broad lineup of medicines. Instead, it spends its time and money on research, lab development, and clinical testing, then seeks regulatory approval and, if successful, would earn money by commercializing its own therapies or through partnerships. Its main “customers” are really the patients, doctors, and hospitals that would use its drugs if they reach the market. What makes Passage Bio different is that it sits very early in the drug-development chain and is built around a small number of highly targeted genetic programs. That means its value comes from turning scientific ideas into approved treatments, not from manufacturing large-volume products or running a traditional drug-sales business.
Passage Bio is a biotechnology company that develops gene therapies for rare genetic diseases, especially disorders that affect the brain and nervous system. Its main work is to design treatments that replace or repair faulty genes, with a focus on diseases that have few or no good treatment options.
The company does not sell a broad lineup of medicines. Instead, it spends its time and money on research, lab development, and clinical testing, then seeks regulatory approval and, if successful, would earn money by commercializing its own therapies or through partnerships. Its main “customers” are really the patients, doctors, and hospitals that would use its drugs if they reach the market.
What makes Passage Bio different is that it sits very early in the drug-development chain and is built around a small number of highly targeted genetic programs. That means its value comes from turning scientific ideas into approved treatments, not from manufacturing large-volume products or running a traditional drug-sales business.
Strong Cash Runway: Passage Bio ended 2022 with $189.6 million in cash, expected to fund operations into the first half of 2025.
Clinical Progress: The company advanced its two lead gene therapy programs, with new positive interim data in GM1 gangliosidosis and plans to dose additional patients at higher levels.
Key 2023 Milestones: Initial data readouts for high-dose infantile GM1 and the first cohort of the FTD trial are targeted for mid and late 2023, respectively.
Study Design Adjustments: Passage Bio is revising inclusion criteria to focus on earlier-stage GM1 patients and increasing dosing to optimize outcomes based on biomarker responses.
Cost Controls: Streamlined operations led to a significant reduction in both R&D and G&A expenses year-over-year.
Regulatory Strategy: The company will discuss registrational study design with regulators after generating additional high-dose patient data, delaying such conversations to 2024.
